Skip to main content

Ocular Therapeutix

Ocular Therapeutix Inc is an American biopharmaceutical company focused on formulation and commercialization of bioresorbable therapies for ophthalmic diseases. The company utilizes its proprietary hydrogel platform to deliver sustained-release drugs, featuring its commercial product Dextenza for post-surgical ocular inflammation and allergic conjunctivitis. Revenue is generated from commercial sales of ophthalmic drug inserts to pharmaceutical wholesalers alongside research collaboration agreements. Core end markets encompass ophthalmology clinics, ambulatory surgical centers, and eye hospitals in the United States. Ocular Therapeutix holds an established position as an innovator in sustained-release hydrogel drug delivery for eye care. The company is headquartered in Bedford, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.

5 of the funds FundTelligence covers report a position in Ocular Therapeutix.

Legal name
Ocular Therapeutix Inc
Sector
Health Care
Country
United States
Funds holding it
5
Exposure themes
Ageing & Longevity, Healthy Ageing & Function, Vision

Funds holding Ocular Therapeutix

Loading...